Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 228

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Machine learning applications in drug development

Open access
Réda, Clémence, Kaufmann, Emilie, Delahaye-Duriez, Andrée · 2020 · Computational and Structural Biotechnology Journal

Abstract

Due to the huge amount of biological and medical data available today, along with well-established machine learning algorithms, the design of largely automated drug development pipelines can now be envisioned. These pipelines may guide, or speed up, drug discovery; provide a better understanding of diseases and associated biological phenomena; help planning preclinical wet-lab experiments, and even future clinical trials. This automation of the drug development process might be key to the current issue of low productivity rate that pharmaceutical companies currently face. In this survey, we will particularly focus on two classes of methods: sequential learning and recommender systems, which are active biomedical fields of research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.csbj.2019.12.006

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 87

  1. Eliopoulos H., Giranda V., Carr R., Tiehen R., Leahy T. and Gordon G.: Phase 0 trials: an industry perspective. Clin Cancer Res 2008; 14: 3683. · doi:10.1158/1078-0432.ccr-07-4586
  2. 10.7150/ijbs.24612 · DOI · Paper page
  3. Schuhmacher A., Gassmann O. and Hinder M.: Changing R&D models in research-based pharmaceutical companies. J Transl Med 2016; 14: 105. · DOI · Paper page
  4. Hwang T.J., Carpenter D., Lauffenburger J.C., Wang B., Franklin J.M. and Kesselheim A.S.: Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Internal Med 2016; 176: 1826. · DOI · Paper page
  5. Pharmaprojects. Pharma r&d annual review 2018. Available at: pharmaintelligence.informa.com/~/media/informa-shop-window/pharma/files/infographics/pharmaprojects-2018-pharma-rd-infographic.pdf. Accessed [September 16 2019].
  6. Meekings K.N., Williams C.S. and Arrowsmith J.E.: Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discovery Today 2012; 17: 660. · DOI · Paper page
  7. Waterfield P. How Is Machine Learning Accelerating Drug Development? Available at: journal.binarydistrict.com/how-is-machine-learning-accelerating-drug-development. Accessed [September 16 2019].
  8. Chan H.S., Shan H., Dahoun T., Vogel H. and Yuan S.: Advancing drug discovery via artificial intelligence. Trends Pharmacol Sci 2019; .
  9. 10.1038/nrd.2017.226 · DOI · Paper page
  10. 10.1101/gr.3851306 · DOI
  11. Hodos R.A., Kidd B.A., Khader S., Readhead B.P. and Dudley J.T.: Computational approaches to drug repurposing and pharmacology. Wiley Interdiscip Rev Syst Biol Med 2016; 8: 186. · DOI · Paper page
  12. Musa A., Ghoraie L.S., Zhang S.D., Glazko G., Yli-Harja O., Dehmer M. et al: A review of connectivity map and computational approaches in pharmacogenomics. Brief Bioinf 2017; 19: 506.
  13. Srivastava P.K., van Eyll J., Godard P., Mazzuferi M., Delahaye-Duriez A., Van Steenwinckel J. et al: A systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target. Nat Commun 2018; 9: 3561. · DOI
  14. 10.1021/acs.molpharmaceut.6b00248 · DOI · Paper page
  15. Schölkopf B., Tsuda K. and Vert J.P.: Support vector machine applications in computational biology. : MIT Press 2004.
  16. 10.1016/j.drudis.2018.01.039 · DOI · Paper page
  17. Lattimore T Szepesvári C. Bandit algorithms; 2018. preprint.
  18. Kaufmann E. and Garivier A.: Learning the distribution with largest mean: two bandit frameworks. ESAIM: Proceed Surveys 2017; 60: 114. · DOI
  19. Mary J Gaudel R Preux P. Bandits and recommender systems. In: International Workshop on Machine Learning Optimization and Big Data; 2015. Springer Cham. p. 325–36. · DOI
  20. Guillou F., Gaudel R. and Preux P.: Large-scale bandit recommender system.. In: International workshop on machine learning, optimization, and big data. Cham: Springer 2016: 204. · DOI
  21. Adomavicius G. and Tuzhilin A.: Toward the next generation of recommender systems: a survey of the state-of-the-art and possible extensions. IEEE Trans Knowl Data Eng 2005; 6: 734. · DOI · Paper page
  22. Brynjolfsson E Hu YJ Smith MD. The longer tail: The changing shape of Amazon’s sales distribution curve; 2010. Available at SSRN 1679991. · DOI
  23. Smith B. and Linden G.: Two decades of recommender systems at Amazon. com. IEEE Internet Comput 2017; 21: 12. · DOI · Paper page
  24. Li L Chu W Langford J Schapire RE. A contextual-bandit approach to personalized news article recommendation. In: Proceedings of the 19th international conference on world wide web; 2010 ACM. p. 661–70. · DOI · Paper page
  25. Rifaioglu AS Atas H Martin MJ Cetin-Atalay R Atalay V Dogan T. Recent applications of deep learning and machine intelligence on in silico drug discovery: methods tools and databases. Brief Bioinform; 2018 10. · DOI · Paper page
  26. Ferrero E., Dunham I. and Sanseau P.: In silico prediction of novel therapeutic targets using gene–disease association data. J Transl Med 2017; 15: 182. · DOI
  27. Celesti F Celesti A Carnevale L Galletta A Campo S Romano A et al. Big data analytics in genomics: The point on Deep Learning solutions. In: 2017 IEEE Symposium on Computers and Communications (ISCC); 2017. IEEE. p. 306–9. · DOI
  28. Riniker S., Wang Y., Jenkins J.L. and Landrum G.A.: Using information from historical high-throughput screens to predict active compounds. J Chem Inf Model 2014; 54: 1880. · DOI
  29. Zou J., Huss M., Abid A., Mohammadi P., Torkamani A. and Telenti A.: A primer on deep learning in genomics. Nat Genet 2018; 1.
  30. Goodfellow I Pouget-Abadie J Mirza M Xu B Warde-Farley D Ozair S et al. Generative adversarial nets. In: Advances in neural information processing systems; 2014. p. 2672–80.
  31. Killoran N Lee LJ Delong A Duvenaud D Frey BJ. Generating and designing DNA with deep generative models; 2017. arXiv preprint arXiv:1712.06148. · arXiv
  32. Gupta A Zou J. Feedback GAN (FBGAN) for DNA: A novel feedback-loop architecture for optimizing protein functions; 2018. arXiv preprint arXiv:1804.01694. · arXiv
  33. Kandasamy K Krishnamurthy A Schneider J Póczos B. Parallelised bayesian optimisation via Thompson sampling. In: International Conference on Artificial Intelligence and Statistics; 2018. p. 133–42.
  34. Griffiths RR Hernández-Lobato JM. Constrained bayesian optimization for automatic chemical design; 2017. arXiv preprint arXiv:1709.05501. · arXiv
  35. Anand N Huang P. Generative modeling for protein structures. In: Advances in neural information processing systems; 2018. p. 7494–7505.
  36. Gonzalez J Longworth J James DC Lawrence ND. Bayesian optimization for synthetic gene design; 2015. arXiv preprint arXiv:1505.01627. · arXiv
  37. Pyzer-Knapp E.O.: Bayesian optimization for accelerated drug discovery. IBM J Res Dev 2018; 62: 2.
  38. Benhenda M. ChemGAN challenge for drug discovery: can AI reproduce natural chemical diversity?; 2017. arXiv preprint arXiv:1708.08227. · DOI
  39. Grimm D. U.S. EPA to eliminate all mammal testing by 2035. Available at: sciencemag.org/news/2019/09/us-epa-eliminate-all-mammal-testing-2035. Accessed [September 13 2019]. · DOI
  40. Aziz M Kaufmann E Riviere MK. On Multi-Armed Bandit Designs for Phase I Clinical Trials; 2019. arXiv preprint arXiv:1903.07082. · arXiv
  41. Berry S.M., Carlin B.P., Lee J.J. and Muller P.: Bayesian adaptive methods for clinical trials. : CRC Press 2010. · DOI · Paper page
  42. Satlin A., Wang J., Logovinsky V., Berry S., Swanson C., Dhadda S. et al: Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer’s disease. Alzheimer’s Dementia: Transl Res Clin Intervent 2016; 2: 1.
  43. 10.1080/00031305.1987.10475458 · DOI
  44. Lai T.L. and Robbins H.: Asymptotically efficient adaptive allocation rules. Adv Appl Math 1985; 6: 4. · DOI · Paper page
  45. Berry D.A. and Fristedt B.: Bandit problems: sequential allocation of experiments (monographs on statistics and applied probability). London: Chapman and Hall 1985: 71. · DOI · Paper page
  46. Jennison C., Johnstone I.M. and Turnbull B.W.: Asymptotically optimal procedures for sequential adaptive selection of the best of several normal means. In: Statistical decision theory and related topics III. : Academic Press 1982: 55. · doi:10.1016/b978-0-12-307502-4.50010-6
  47. Bechhofer R.E.: A single-sample multiple decision procedure for ranking means of normal populations with known variances. Ann Math Stat 1954; : 16. · DOI · Paper page
  48. Even-Dar E., Mannor S. and Mansour Y.: Action elimination and stopping conditions for the multi-armed bandit and reinforcement learning problems. J Machine Learn Res 2006; 7: 1079.
  49. Bubeck S., Munos R. and Stoltz G.: Pure exploration in finitely-armed and continuous-armed bandits. Theoret Comput Sci 2011; 412: 1832. · DOI · Paper page
  50. Hardwick J. and Stout Q.F.: Bandit strategies for ethical sequential allocation. Comp Sci Stat 1991; 23: 421.
  51. Armitage P.: The search for optimality in clinical trials. Int Statist Rev/Rev Int Statist 1985; : 15. · DOI
  52. Villar S.S., Bowden J. and Wason J.: Multi-armed bandit models for the optimal design of clinical trials: benefits and challenges. Stat Sci 2015; 30: 199. · DOI · Paper page
  53. Villar S.S.: Bandit strategies evaluated in the context of clinical trials in rare life-threatening diseases. Probab Eng Inf Sci 2018; 32: 229. · DOI
  54. Chapelle O Li L. An empirical evaluation of Thompson sampling. In: Advances in neural information processing systems; 2011. p. 2249–57).
  55. Thall P.F. and Wathen J.K.: Practical Bayesian adaptive randomisation in clinical trials. Eur J Cancer 2007; 43: 859. · DOI · Paper page
  56. 10.1038/nrd1927 · DOI · Paper page
  57. Varatharajah Y Berry B Koyejo S Iyer R. A Contextual-bandit-based Approach for Informed Decision-making in Clinical Trials; 2018. arXiv preprint arXiv:1809.00258. · arXiv
  58. Durand A Achilleos C Iacovides D Strati K Mitsis GD Pineau J. Contextual bandits for adapting treatment in a mouse model of de novo carcinogenesis. In: Machine learning for healthcare conference; 2018 p. 67–82.
  59. 10.1093/bib/bbr005 · DOI · Paper page
  60. Bisgin H., Liu Z., Kelly R., Fang H., Xu X. and Tong W.: Investigating drug repositioning opportunities in FDA drug labels through topic modeling. In BMC bioinformatics. BioMed Central 2012; 13: S6.
  61. Tari L.B. and Patel J.H.: Systematic drug repurposing through text mining. In: Biomedical Literature Mining. New York, NY: Humana Press 2014: 253. · DOI
  62. Alaimo S., Giugno R. and Pulvirenti A.: Recommendation techniques for drug–Target interaction prediction and drug repositioning. In: Data mining techniques for the life sciences. New York, NY: Humana Press 2016: 441. · DOI
  63. 10.1093/bib/bbr021 · DOI · Paper page
  64. Zhang W., Yue X., Huang F., Liu R., Chen Y. and Ruan C.: Predicting drug-disease associations and their therapeutic function based on the drug-disease association bipartite network. Methods 2018; 145: 51. · DOI
  65. Gilvary C., Madhukar N., Elkhader J. and Elemento O.: The missing pieces of artificial intelligence in medicine. Trends Pharmacol Sci 2019; . · DOI
  66. 10.1016/j.inffus.2018.09.012 · DOI · Paper page
  67. Carvalho-Silva D., Pierleoni A., Pignatelli M., Ong C., Fumis L., Karamanis N. et al: Open targets platform: new developments and updates two years on. Nucleic Acids Res 2018; 47: D1056. · DOI · Paper page
  68. Davis A.P., Grondin C.J., Johnson R.J., Sciaky D., McMorran R., Wiegers J. et al: The comparative toxicogenomics database: update 2019. Nucleic Acids Res 2018; 47: D948. · DOI · Paper page
  69. Piñero J., Bravo À., Gutiérrez-Sacristán A., Centeno E., Deu-Pons J. and García J.: DisGeNET, a centralized repository of the genetic basis of human diseases. F1000Research 2017; 6.
  70. 10.1093/dnares/dsl005 · DOI
  71. Boué S., Talikka M., Westra J.W., Hayes W., Di Fabio A., Park J. et al: Causal biological network database: a comprehensive platform of causal biological network models focused on the pulmonary and vascular systems. Database 2015; 2015. · DOI
  72. 10.1126/science.1132939 · DOI · Paper page
  73. Li Y.H., Yu C.Y., Li X.X., Zhang P., Tang J., Yang Q. et al: Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics. Nucleic Acids Res 2017; 46: D1121. · DOI · Paper page
  74. Von Eichborn J., Murgueitio M.S., Dunkel M., Koerner S., Bourne P.E. and Preissner R.: PROMISCUOUS: a database for network-based drug-repositioning. Nucleic Acids Res 2010; 39: D1060. · DOI · Paper page
  75. 10.1038/sdata.2017.29 · DOI · Paper page
  76. 10.1093/nar/gky092 · DOI · Paper page
  77. Gaulton A., Hersey A., Nowotka M., Bento A.P., Chambers J., Mendez D. et al: The ChEMBL database in 2017. Nucleic Acids Res 2016; 45: D945. · DOI · Paper page
  78. Koscielny S.: Why most gene expression signatures of tumors have not been useful in the clinic. Sci Transl Med 2010; 2. · DOI
  79. Guyon I. and Elisseeff A.: An introduction to variable and feature selection. J Machine Learn Res 2003; 3: 1157.
  80. Zeng X., Zhu S., Liu X., Zhou Y., Nussinov R. and Cheng F.: deepDR: a network-based deep learning approach to in silico drug repositioning. Bioinformatics 2019; .
  81. Delahaye-Duriez A., Srivastava P., Shkura K., Langley S.R., Laaniste L., Moreno-Moral A. et al: Rare and common epilepsies converge on a shared gene regulatory network providing opportunities for novel antiepileptic drug discovery. Genome Biol 2016; 17: 245. · DOI
  82. Ahmed SS Roy S Kalita JK. Assessing the effectiveness of causality inference methods for gene regulatory networks. IEEE/ACM transactions on computational biology and bioinformatics; 2018.
  83. Young WC Yeung KY Raftery AE. A posterior probability approach for gene regulatory network inference in genetic perturbation data; 2016. arXiv preprint arXiv:1603.04835. · DOI
  84. Tardif J.C., Rhainds D., Brodeur M., Feroz Zada Y., Fouodjio R., Provost S. et al: Genotype-dependent effects of dalcetrapib on cholesterol efflux and inflammation: concordance with clinical outcomes. Circulation: Cardiovascular. Genetics 2016; 9: 340.
  85. Burki T.: Pharma blockchains AI for drug development. Lancet 2019; 393: 2382. · doi:10.1016/s0140-6736(19)31401-1
  86. Brown A.S., Kong S.W., Kohane I.S. and Patel C.J.: ksRepo: a generalized platform for computational drug repositioning. BMC Bioinf 2016; 17: 78. · DOI
  87. Pallmann P., Bedding A.W., Choodari-Oskooei B., Dimairo M., Flight L., Hampson L.V. et al: Adaptive designs in clinical trials: why use them, and how to run and report them. BMC medicine 2018; 16: 29. · DOI · Paper page

Cited by

Metadata

Authors
Réda, C., Kaufmann, E., & Delahaye-Duriez, A.
Venue
Computational and Structural Biotechnology Journal
Published
2020
Volume
18
Pages
241-252
ISSN
2001-0370 (ISSN-L)
OpenAlex
W2997578645
Cited by
228
References
21
FWCI
17.68
Type
journal article
Language
en
Open access
gold
Licence
Funders
  • Centre National de la Recherche Scientifique
  • Agence Nationale de la Recherche

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.